CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Morgan Stanley 22nd Annual Global Healthcare Conference
1x1 Investor Meetings: Friday, September 6, 2024
Location: New York, NY
Baird 2024 Global Healthcare Conference
Fireside Chat: Wednesday, September 11, 2024, at 7:55am ET
Location: New York, NY
Chardan’s 8th Annual Genetic Medicines Conference
Fireside Chat: Monday, September 30, 2024, at 4:30pm ET
Location: New York, NY
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$22.41 |
| Daily Change: | -1.70 -7.05 |
| Daily Volume: | 142,544 |
| Market Cap: | US$153.510M |
October 22, 2025 October 17, 2025 October 16, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
